Anti-FANCI Antibody, (G4270)

Evaluated by Western Blotting in K562 nuclear extract.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected FANCI in 10 µg of K562 nuclear extract.

Anti-FANCI (G4270), Cat. No. ABE1817, is a highly specific rabbit polyclonal antibody that targets FANCI and has been tested in Western Blotting.

Research Category
Epigenetics & Nuclear Function

Western Blotting Analysis: 1.4 µg/mL from a representative lot detected exogenously expressed FANCI in transfected, but not untransfected FANCI-deficient EUFA1301 cells (kindly provided by Dr. Johan de Winter) with or without 24-hour 60 ng/ml mitomycin C (MMC) treatment (Courtesy of Martin Cohn, Ph.D., Department of Biochemistry, University of Oxford, UK).

Western Blotting Analysis: 1.4 µg/mL from a representative lot detected endogenous FANCI in FANCD2-deficient EUFA1421 (kindly provided by Dr. Johan de Winter) cells. Exogenous FANCD2 expression stabilized FANCI and monoubiquitinated FANCI was detectable upoon 24-hour 60 ng/ml mitomycin C (MMC) treatment of FANCD2 transfectants (Courtesy of Martin Cohn, Ph.D., Department of Biochemistry, University of Oxford, UK).

Western Blotting Analysis: 1.4 µg/mL from a representative lot detected monoubiquitinated FANCI mainly in the nuclear fraction of FANCD2-deficient EUFA1421 cells (kindly provided by Dr. Johan de Winter) upon exogenous FANCD2 expression with or without additional 24-hour 60 ng/ml mitomycin C (MMC) treatment (Courtesy of Martin Cohn, Ph.D., Department of Biochemistry, University of Oxford, UK).

This polyclonal antibody detected the expected target band only in lysate from FANCI-tranfected, but not untransfected FANCI-deficient EUFA1301 cells.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Fanconi anemia group I protein (UniProt Q9NVI1; also known as Protein FACI) is encoded by the FANCI (also known as KIAA1794) gene (Gene ID 55215) in human. It plays a vital role in the repair of DNA double-strand breaks by homologous recombination and in the repair of interstrand DNA cross-links (ICLs) by promoting FANCD2 monoubiquitination by FANCL and participating in recruitment to DNA repair sites. It is also required for maintenance of chromosomal stability. FACI is reported to participate in S phase and G2 phase checkpoint activation upon DNA damage. It is monoubiquitinated by FANCL on Lys-523 during S phase and upon genotoxic stress and is deubiquitinated by USP1 as cells enter G2/M or once the DNA repair is completed. Mutations in the FANCI gene are known to cause Fanconi anemia, a developmental and cancer-predisposition syndrome. Ref: Smogorzewska A., et al. (2007) Cell 129, 289-301.

~160 kDa observed. 149.3 kDa calculated. Uncharacterized bands may be observed in some lysate(s).

Synthetic peptide corresponding to an internal sequence within the N-terminal half of human FANCI.

Concentration: Please refer to lot specific datasheet.

Affinity purified.

Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.